Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 1 Drugs
- Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
The continuous progress made in cancer research and immense efforts by researchers have led to recognition of several potential targets which can be used for the development of targeted drugs. Recently, scientists have identified trophoblast cell-surface antigen 2 (TROP2) which is a transmembrane glycoprotein that is overexpressed in several cancers including up to 80% of patients with triple-negative breast cancer, non-small cell lung cancer, colon cancer, prostate, gastric, and urothelial cancers. Apart from its expression, it also plays a critical role in regulating several signaling molecules and participates in signaling pathways associated with tumorigeneses. Thus, researchers developed several drugs which can target the receptor and aids in the management of cancer.
Sacituzumab govitecan/IMMU-132 (Trodelvy) developed by Immunomedics is the first TROP2 targeted drug which have entered the market. Trodelvy is an antibody drug conjugate which consists of humanized anti-Trop2 monoclonal antibody (hRS7), conjugated with active metabolite of irinotecan (SN-38) via a cleavable CL2A linker. It is indicated for the management of for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. As of now, the drug has been introduced into several regions including US, Australia, Canada, UK, and Switzerland whereas it has been designated orphan drug designation in Europe. However, European Medicine Agency has recently recommended the marketing of Trodelvy, indicating that the drug will enter the market in coming months, which will drive the growth of market,
The entry of Trodelvy in the market is expected to show high adoption rates in the market as it is first therapy indicated specifically for metastatic triple negative breast cancer. Apart from this, investigators are also evaluating the role of drug in other cancers including hormone receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer, endometrial carcinoma, urothelial cancer, glioblastoma and hepatocellular carcinoma. Additional clinical trials are also evaluating the combination of drug with talazoparib, nivolumab, carboplatin, and other cancer therapeutics to enhance the efficacy of the drug.
The great enthusiasm by researchers has further led to the development of strong pipeline of TROP2 targeting drugs which are expected to enter the market during the forecast period. Several potential candidates including DS-1062a, RN927C, BAT8003, SKB264, and JS108 have been developed which have shown positive preclinical and clinical results. Furthermore, several pharmaceutical giants in the market have also adopted strategic alliances such as collaborations, partnerships, or joint ventures to cope up with the high cost of research and development and to maintain their share in market. For instance, Daiichi Sankyo and AstraZeneca have recently announced second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) and Keytruda in non-small cell lung cancer patients.
As per report findings, it was demonstrated that the global Trop2 inhibitor market is anticipated to surpass USd 3 Billion by 2026. Several factors such as increase in prevalence of cancer, rise in geriatric population, huge investment in research and development sector, and increasing awareness about the availability of novel therapies will drive the growth of market. The overall market is highly competitive and consists of several major players including Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, and BioThera Solution. In addition, US market is expected to hold majority share owing to high incidences of cancer, high acceptance to novel therapies, and favorable reimbursement policies. The Asia-Pacific market on the other hand expected to be the fastest-growing regional segment during the forecast period due to the presence of many emerging players, less-stringent regulations, and increasing cooperation among leading and regional players for development of novel targeted drugs.